Pancreatic Prostate Articles & Analysis
5 news found
Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ovarian, gastric, prostate, pancreatic, liver, and kidney cancers. He also discusses several of the company’s near-term pipeline products and other areas of possible ...
“Our SubB2M technology can be applied to detect and monitor other cancers in addition to breast and ovarian cancers, such as colorectal, prostate, pancreatic and melanoma. “Using a next-generation benchtop SPR instrument, we are also evaluating SubB2M as a pan-cancer indicator in a general health ...
"This project has the potential to springboard advanced next-generation sequencing to routine clinical use in Ontario and across Canada." Breast and prostate cancer are among the most common types of cancer in Canada, and the country's five-year net survival rate for pancreatic cancer is only 8 percent. ...
All four of Celixir’s siRNA molecules block the novel intracellular cancer target, STAT6, which is expressed in hard to treat and drug-resistant cancers, such as colon, breast, lung, pancreatic and prostate cancers, and is typically associated with an increased malignancy and poor prognosis. ...
In numerous collaborative studies, Predictive Diagnostics has demonstrated the capability of its BAMF™ technology to accurately diagnose cancers such as breast, lung, pancreatic and prostate, as well as multiple sclerosis. Predictive Diagnostics believes its diagnostic tests will provide better patient outcome through early detection of cancer and other serious ...